keyword
MENU ▼
Read by QxMD icon Read
search

interferon lambda

keyword
https://www.readbyqxmd.com/read/28315743/treatment-with-peg-ifn-and-ribavirin-in-patients-with-chronic-hepatitis-c-low-grade-of-hepatic-fibrosis-genotype-1-and-4-and-favorable-ifnl3-genotype-a-pharmacogenetic-prospective-study
#1
Lucio Boglione, Chiara Simona Cardellino, Jessica Cusato, Amedeo De Nicolò, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
The new direct-acting antivirals agents (DAAs) rapidly changed the treatment approach in chronic hepatitis C (CHC); however, the interferon (IFN)-free therapies availability is currently different in some countries, due to higher costs of these drugs. Naïve treated patients, who are not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated (PEG)-IFN and ribavirin (RBV), through IFN lambda 3 gene polymorphisms and fibrosis stage evaluation. Inclusion criteria were: naïve treated CHC patients with GT1 or GT4, without major contraindication to PEG-IFN or RBV, with fibrosis stage F0-F2 and IFNL3 rs8099917/rs12979860 TT/CC genotypes...
March 15, 2017: Infection, Genetics and Evolution
https://www.readbyqxmd.com/read/28293236/interferon-lambda-modulating-immunity-in-infectious-diseases
#2
REVIEW
Mohammedyaseen Syedbasha, Adrian Egli
Interferon lambdas (IFN-λs; IFNL1-4) modulate immunity in the context of infections and autoimmune diseases, through a network of induced genes. IFN-λs act by binding to the heterodimeric IFN-λ receptor (IFNLR), activating a STAT phosphorylation-dependent signaling cascade. Thereby hundreds of IFN-stimulated genes are induced, which modulate various immune functions via complex forward and feedback loops. When compared to the well-characterized IFN-α signaling cascade, three important differences have been discovered...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28282271/safety-and-efficacy-of-pegylated-interferon-lambda-ribavirin-and-daclatasvir-in-hcv-and-hiv-coinfected-patients
#3
Mark Nelson, Rafael Rubio, Adriano Lazzarin, Svetlana Romanova, Annie Luetkemeyer, Brian Conway, Jean-Michel Molina, Dong Xu, Subasree Srinivasan, Simon Portsmouth
To evaluate the efficacy and safety of pegylated interferon-lambda-1a (Lambda)/ribavirin (RBV)/daclatasvir (DCV) for treatment of patients coinfected with chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Treatment-naive patients were assigned to cohort A [HCV genotype (GT)-2 or -3] or cohort B [HCV GT-1(a or b) or -4]. All patients received Lambda/RBV/DCV for the first 12 weeks; cohort A received Lambda/RBV for an additional 12 weeks, followed by 24 weeks of follow-up, and cohort B received response-guided therapy...
March 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28274837/a-novel-method-for-detection-of-ifn-lambda-3-binding-to-cells-for-quantifying-ifn-lambda-receptor-expression
#4
Deanna M Santer, Gillian E S Minty, Adil Mohamed, Lesley Baldwin, Rakesh Bhat, Michael Joyce, Adrian Egli, D Lorne J Tyrrell, Michael Houghton
Type III interferons (IFN-lambdas) are important antiviral cytokines that also modulate immune responses acting through a unique IFN-λR1/IL-10R2 heterodimeric receptor. Conflicting data has been reported for which cells express the IFN-λR1 subunit and directly respond to IFN-λs. In this study we developed a novel method to measure IFN-λ3 binding to IFN-λR1/IL-10R2 on the surface of cells and relate this to a functional readout of interferon stimulated gene (ISG) activity in various cell lines. We show that Huh7...
March 5, 2017: Journal of Immunological Methods
https://www.readbyqxmd.com/read/28263098/type-iii-interferons-and-rheumatoid-arthritis-correlation-between-interferon-lambda-1-interleukin-29-and-antimutated-citrullinated-vimentin-antibody-levels
#5
Diana Castillo-Martínez, Maribel Juarez, Mariana Patlán, Araceli Páez, Felipe Massó, Luis M Amezcua-Guerra
AIM: To assess serum type III or lambda (λ) interferons (IFN) levels and its clinical and laboratory associations in rheumatoid arthritis (RA). METHODS: A cross-sectional study including 43 patients with RA (86% females; age 45.3 ± 10.3 years) and 43 healthy individuals was performed. Clinical data including disease activity, acute-phase reactants, rheumatoid factor and anticyclic citrullinated peptide (anti-CCP) antibodies were collected. Serum IFNλ1, IFNλ2, IFNλ3, CXCL8 and anti-mutated citrullinated vimentin (anti-MCV) antibody levels were measured...
March 2017: Autoimmunity
https://www.readbyqxmd.com/read/28255563/the-role-of-type-iii-interferons-in-hepatitis-c-virus-infection-and-therapy
#6
REVIEW
Janina Bruening, Bettina Weigel, Gisa Gerold
The human interferon (IFN) response is a key innate immune mechanism to fight virus infection. IFNs are host-encoded secreted proteins, which induce IFN-stimulated genes (ISGs) with antiviral properties. Among the three classes of IFNs, type III IFNs, also called IFN lambdas (IFNLs), are an essential component of the innate immune response to hepatitis C virus (HCV). In particular, human polymorphisms in IFNL gene loci correlate with hepatitis C disease progression and with treatment response. To date, the underlying mechanisms remain mostly elusive; however it seems clear that viral infection of the liver induces IFNL responses...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28250263/lambda-interferons-inhibit-herpes-simplex-virus-type-2-replication-in-human-cervical-epithelial-cells-through-activation-of-jak-stat-pathway
#7
Zhu Li, Xuan Lu, Yufan Zhu, Pengfei Cheng, Shi Liu, Yi Zhang, Jingfeng Tang, Sijun Yang, Li Zhou
Herpes Simplex Virus Type 2 (HSV-2) is associated with a variety of diseases, resulting in world-wide health problems. Our early study showed that lambda-interferons (IFN-λs) induced by activation of the toll-like receptors 3/ retinoic acid-inducible protein I (TLR3/RIG-I) signaling pathways contribute to inhibition of HSV-2 replication in the human cervical epithelial cells. However, anti-HSV-2 mechanisms and specific differences in signaling transduction by different IFN-λs in human cervical epithelial cells are unclear...
February 28, 2017: Japanese Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28122304/synergy-with-interferon-lambda-3-and-sorafenib-suppresses-hepatocellular-carcinoma-proliferation
#8
Yuke Yan, Liang Wang, Jingjing He, Pengcheng Liu, Xi Lv, Yawu Zhang, Xiaodong Xu, Lingyi Zhang, Youcheng Zhang
Hepatocellular carcinoma (HCC) is a common and fatal malignancy of the liver. Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC. However, some advanced HCC patients fail to respond to sorafenib, and those who do lack a meaningful clinical benefit. Interferon-lambda 3 (IFN-λ3) is a type III interferon with antiviral, antiproliferative, and immunomodulatory functions. Here, we evaluated the use of IFN-λ3 as an adjuvant treatment with sorafenib in HCC...
April 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28109912/ifn-lambda-preferably-inhibits-pedv-infection-of-porcine-intestinal-epithelial-cells-compared-with-ifn-alpha
#9
Lin Li, Fang Fu, Mei Xue, Weiye Chen, Jin Liu, Hongyan Shi, Jianfei Chen, Zhigao Bu, Li Feng, Pinghuang Liu
In contrast to type I interferons that target various types of cells and organs, interferon lambda (IFN-L) primarily acts on mucosal epithelial cells and exhibits robust antiviral activity within the mucosal surface. Porcine epidemic diarrhea virus (PEDV), which causes high morbidity and mortality in piglets, is an enteropathogenic coronavirus with economic importance. Here, we demonstrated that both recombinant porcine IFN-L1 (rpIFN-L1) and rpIFN-L3 have powerful antiviral activity against PEDV infection of both Vero E6 cells and the intestinal porcine epithelial cell line J2 (IPEC-J2)...
April 2017: Antiviral Research
https://www.readbyqxmd.com/read/28077655/expression-of-ifnlr1-on-intestinal-epithelial-cells-is-critical-to-the-antiviral-effects-of-interferon-lambda-against-norovirus-and-reovirus
#10
Megan T Baldridge, Sanghyun Lee, Judy J Brown, Nicole McAllister, Kelly Urbanek, Terence S Dermody, Timothy J Nice, Herbert W Virgin
Lambda interferon (IFN-λ) has potent antiviral effects against multiple enteric viral pathogens, including norovirus and rotavirus, in both preventing and curing infection. Because the intestine includes a diverse array of cell types, however, the cell(s) upon which IFN-λ acts to exert its antiviral effects is unclear. Here, we sought to identify IFN-λ-responsive cells by generation of mice with lineage-specific deletion of the receptor for IFN-λ, Ifnlr1 We found that expression of IFNLR1 on intestinal epithelial cells (IECs) in the small intestine and colon is required for enteric IFN-λ antiviral activity...
April 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/28036111/hepatic-ifnl4-expression-is-associated-with-non-response-to-interferon-based-therapy-through-the-regulation-of-basal-interferon-stimulated-gene-expression-in-chronic-hepatitis-c-patients
#11
Miyako Murakawa, Yasuhiro Asahina, Fukiko Kawai-Kitahata, Mina Nakagawa, Sayuri Nitta, Satoshi Otani, Hiroko Nagata, Shun Kaneko, Yu Asano, Tomoyuki Tsunoda, Masato Miyoshi, Yasuhiro Itsui, Seishin Azuma, Sei Kakinuma, Yasuhito Tanaka, Sayuki Iijima, Kaoru Tsuchiya, Namiki Izumi, Shuji Tohda, Mamoru Watanabe
Single nucleotide polymorphisms (SNPs) within or near interferon lambda 4 (IFNL4) gene located upstream of IFNL3 are associated with response to anti-HCV therapy both in interferon (IFN)-based and IFN-free regimens. IFNL4 encodes IFNλ4, a newly discovered type III IFN, and its expression is controlled by rs368234815-TT/ΔG, which is in strong linkage disequilibrium (LD) with other tag SNPs within or near IFNL4 such as rs12979860 and rs8099917. Intrahepatic expression levels of IFN-stimulated genes (ISGs) affect the responsiveness to IFNα and are also associated with IFNL4 genotype...
December 30, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27986689/hla-b-57-and-ifnl4-related-polymorphisms-are-associated-with-protection-against-hiv-1-disease-progression-in-controllers
#12
B Dominguez-Molina, L Tarancon-Diez, S Hua, C Abad-Molina, E Rodriguez-Gallego, K Machmach, F Vidal, C Tural, S Moreno, J M Goñi, E Ramírez de Arellano, M Del Val, M F Gonzalez-Escribano, J Del Romero, C Rodriguez, L Capa, P Viciana, J Alcamí, X G Yu, B D Walker, Manuel Leal, M Lichterfeld, E Ruiz-Mateos
BACKGROUND: HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL) without antiretroviral treatment. However, some HIV-1-controllers have evidence of immunologic progression with marked CD4(+)T-cell decline. We investigated host genetic factors associated with protection against CD4(+)T-cell loss in HIV-1-controllers. METHODS: We analysed the association of interferon lambda 4 (IFNL4)-related polymorphisms and HLA-B haplotypes within Long Term Non-Progressor HIV-1-controllers ((LTNP-C), defined by maintaining CD4(+)T-cells counts >500 cells/mm(3) for more than 7 years after HIV-1 diagnosis) versus non-LTNP-C, who developed CD4(+)T-cells counts <500 cells/mm(3) Both a Spanish study cohort (n=140) and an international validation cohort (n=914) were examined...
December 16, 2016: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27904617/the-interferon-lambda-4-rs368234815-predicts-treatment-response-to-pegylated-interferon-alpha-and-ribavirin-in-hemophilic-patients-with-chronic-hepatitis-c
#13
Maryam Keshvari, Seyed Moayed Alavian, Bita Behnava, Ali Pouryasin, Heidar Sharafi
BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-α) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). MATERIALS AND METHODS: In this retrospective study, 92 hemophilic patients with CHC who were treated with Peg-IFN-α/RBV were investigated...
2016: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/27844277/chronic-hepatitis-c-virus-infection-in-india-regional%C3%A2-demographics-and-distribution-of-viral-genotypes
#14
Samir R Shah, P N Rao, Shiv K Sarin, Abhijit Chowdhury, Shobna Bhatia, Rajesh Dharamsi, B D Goswami, Dharmesh Kapoor, Rosang Luaia, Rajiv Mehta, Shrikant Mukewar, V G Mohan Prasad, Ramesh Roop Rai, Sanjiv Saigal, Devendra Singh, Nirupama Trehanpati, Sandra Chen, Anuj Gaggar, Steven J Knox, G Mani Subramanian, Shivaram Prasad Singh, Ajit Sood, Joy Varghese, Raj Vigna Venugopal
BACKGROUND AND AIMS: Although chronic hepatitis C virus (HCV) infection affects millions of people in India, few studies have assessed host, viral, and disease characteristics of chronically infected patients at national and regional levels. Such information is critical to support large scale screening and treatment initiatives for chronic HCV infection in India. METHODS: Patients with known chronic HCV infection making routine or for-cause visits to the participating study centers were enrolled in this observational study...
November 2016: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/27833958/clinical-importance-of-pharmacogenetics-in-the-treatment-of-hepatitis-c-virus-infection
#15
Adina Maria Kamal, Paul MitruŢ, Kamal Constantin Kamal, Oana Sorina Tica, Mihaela Niculescu, Dragoş Ovidiu Alexandru, Andrei Adrian Tica
Globally, over 4% of the world population is affected by hepatitis C virus (HCV) infection. The current standard of care for hepatitis C infection is combination therapy with pegylated interferon and ribavirin for 48 weeks, which yield a sustained virological response in only a little over half of the patients with genotype 1 HCV. We investigated the clinical importance of pharmacogenetics in treatment efficacy and prediction of hematotoxicity. A total of 148 patients infected with HCV were enrolled. All patients were treated for a period of 48 weeks or less with pegylated interferon and ribavirin...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27826322/daclatasvir-based-treatment-regimens-for-hepatitis-c-virus-infection-a-systematic-review-and-meta-analysis
#16
REVIEW
Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh
CONTEXT: Direct acting antivirals (DAAs) have recently emerged as a promising therapeutic regimen for the treatment of hepatitis C virus (HCV) infection, which is a major public health problem. Among the known DAAs, daclatasvir (DCV), an inhibitor of the non-structural 5A protein, has been used in combination with several drugs for treatment of infection with HCV of different genotypes under different conditions. We conducted a systematic review and meta-analysis of combination therapy with DCV...
September 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/27810523/correlation-of-interferon-lambda-4-ss469415590-with-the-hepatitis-c-virus-treatment-response-and-its-comparison-with-interleukin-28b-polymorphisms-in-predicting-a-sustained-virological-response-a-meta-analysis
#17
Yunhua Li, Luhua Yang, Kaihui Sha, Tonggang Liu, Liguo Zhang
BACKGROUND: Interferon-lambda 4 (IFNL4) ss469415590 is a newly discovered polymorphism that could predict the treatment response in hepatitis C virus (HCV)-infected patients. This meta-analysis was performed in order to clarify its specific effect on the treatment response and to compare it with interleukin 28b (IL28B). METHOD: The commonly used literature databases were searched. Meta-analyses were performed with fixed/random-effects models using Stata 12.0. The sustained virological response (SVR) rate was summarized using R software...
December 2016: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/27799623/interferon-lambda-4-expression-is-suppressed-by-the-host-during-viral-infection
#18
MeeAe Hong, Johannes Schwerk, Chrissie Lim, Alison Kell, Abigail Jarret, Joseph Pangallo, Yueh-Ming Loo, Shuanghu Liu, Curt H Hagedorn, Michael Gale, Ram Savan
Interferon (IFN) lambdas are critical antiviral effectors in hepatic and mucosal infections. Although IFNλ1, IFNλ2, and IFNλ3 act antiviral, genetic association studies have shown that expression of the recently discovered IFNL4 is detrimental to hepatitis C virus (HCV) infection through a yet unknown mechanism. Intriguingly, human IFNL4 harbors a genetic variant that introduces a premature stop codon. We performed a molecular and biochemical characterization of IFNλ4 to determine its role and regulation of expression...
November 14, 2016: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/27773202/a-single-nucleotide-polymorphism-rs12979860-in-the-non-coding-control-region-of-the-interferon-lambda-gene-cluster-may-affect-the-relative-expression-of-interferon-lambda-2-and-lambda-3
#19
https://www.readbyqxmd.com/read/27749900/a-randomized-study-of-peginterferon-lambda-1a-compared-to-peginterferon-alfa-2a-in-combination-with-ribavirin-and-telaprevir-in-patients-with-genotype-1-chronic-hepatitis-c
#20
Robert Flisiak, Mitchell Shiffman, Juan Arenas, Hugo Cheinquer, Igor Nikitin, Yuping Dong, Khurram Rana, Subasree Srinivasan
BACKGROUND: A randomized, double-blind, multinational, phase 3 study was conducted comparing the efficacy and safety of peginterferon lambda-1a (Lambda)/ribavirin (RBV)/telaprevir (TVR) vs. peginterferon alfa-2a (Alfa)/RBV/TVR in patients with chronic hepatitis C virus (HCV) genotype-1 (GT-1) infection. METHODS: Patients (treatment-naïve or relapsers on prior Alfa/RBV treatment) were randomly assigned in a 2:1 ratio to receive Lambda/RBV/TVR or Alfa/RBV/TVR. Total duration of treatment was either 24 or 48 weeks (response-guided treatment), with TVR administered for the first 12 weeks...
2016: PloS One
keyword
keyword
30898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"